Transcriptomics

Dataset Information

0

Targeting SUMOylation sensitizes Acute myeloid leukemia to Venetoclax treatment


ABSTRACT: Acute myeloid leukemia (AML) is a hematopoietic cancer characterized by the proliferation and accumulation of aberrant immature myeloid progenitor blasts in bone marrow and peripheral blood. Venetoclax (VEN), a selective B-cell lymphoma 2 (BCL-2) inhibitor, has received FDA approval for AML treatment in combination with hypomethylating agents (HMA). However, treatment failure and therapy resistance present an urgent need for new therapies to overcome VEN resistance and enhance VEN efficacy. We propose inhibition of SUMOylation as a novel therapy with the potential to address this need. SUMOylation regulates protein function by covalently attaching Small Ubiquitin-like MOdifier (SUMO) proteins to target proteins via an enzymatic cascade. Our study aims to evaluate the effects of SUMOylation inhibition on anti-AML activity of VEN and dissert the underlying mechanism.

ORGANISM(S): Homo sapiens

PROVIDER: GSE267885 | GEO | 2024/05/27

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-11-12 | GSE183329 | GEO
2020-08-17 | GSE156008 | GEO
2020-08-31 | GSE155431 | GEO
2024-07-25 | PXD050539 | Pride
2024-07-24 | GSE261338 | GEO
2024-07-24 | GSE261337 | GEO
| MSV000092970 | MassIVE
2019-05-03 | GSE125403 | GEO
2023-11-09 | GSE247025 | GEO
2021-04-07 | GSE171552 | GEO